Accuracy Evaluation of the BD FACS Presto System

Becton, Dickinson and Company583 enrolled

Overview

The enumeration of T lymphocytes positive for the CD4 antigen is used to determine the immune status of patients with, or suspected of developing, immune deficiencies such as AIDS. The BD FACS Presto™ is an investigational automated system for in vitro diagnostic use in performing the direct enumeration of CD4 absolute count, CD4 percentage of lymphocytes, and hemoglobin (Hb) concentration in human whole blood. This is a prospective study to determine the relative bias between the investigational BD FACS Presto system and the predicate BD FACS Calibur with BD Tritest system in their determination of absolute CD4, % CD4, and Hb concentrations.

Study Type

OBSERVATIONAL

Enrollment

583

Conditions

Acquired Immunodeficiency Syndrome

Interventions

Investigational BD FACSPresto SystemDEVICE

Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.

Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subject has been infected with HIV and willing to provide informed consent to draw venous and capillary blood * Specimen: Venous blood must be collected in blood collection tube with EDTA anticoagulant and stored at room temperature (20-25 °C) according to tube manufacturer's instructions * Specimen: post enrolment staining within 24 hours * venous blood of acceptable quality for flow cytometry, e.g. no hemolysis or clots and acceptable pre analytical handling) * venous blood sample \> 1 mL for sample preparation * capillary blood applied to the investigational CD4/%CD4/Hb cartridge Exclusion Criteria: * Subject unwilling to disclose medical information regarding previous CD4 test results * Subject unwilling to discuss medical information regarding co-morbid conditions and current medications

Locations (6)

Children's Hospital Los Angeles

Los Angeles, California, United States

San Francisco General Hospital and Trauma Center

San Francisco, California, United States

Becton Dickinson MedLab

San Jose, California, United States

National AIDS Research Institute

Pune, Maharashtra, India

KEMR/CDC Research and Public Health Collaboration

Kisumu, Kenya

Siriraj Hospital

Bangkok, Siriraj, Thailand

Outcomes

Primary Outcomes

Method bias between BD FACSPresto System vs. Predicate in venous blood (AbsCD4 and %CD4)

The primary endpoint is the bias (expected difference) between the investigational vs. predicate system measured as absolute CD4 lymphocyte count and %CD4 in peripheral venous blood from a minimum of 400 specimens with valid results tested at three or more external sites.

Time frame: assayed upon sample collection

Secondary Outcomes

Method bias between BD FACSPresto System vs. Predicate in Capillary Blood (AbsCD4 and %CD4)

The bias (expected difference) between the investigational vs. predicate system measured as absolute CD4 lymphocyte count and %CD4 in capillary blood from a minimum of 400 specimens with valid results tested will be determined at three or more external sites.

Time frame: assayed upon sample collection

Method bias between BD FACSPresto System vs. Predicate for Hemoglobin

The bias (expected difference) between the investigational BD FACSPresto system vs. predicate (Sysmex KX-21 hematology analyzer) will be determined for hemoglobin concentration using venous blood and capillary blood.

Time frame: assayed upon sample collection